133 related articles for article (PubMed ID: 35834400)
21. PI3K Pathway Effectors pAKT and FOXO1 as Novel Markers of Endometrioid Intraepithelial Neoplasia.
Strickland AL; Rivera G; Lucas E; John G; Cuevas I; Castrillon DH
Int J Gynecol Pathol; 2019 Nov; 38(6):503-513. PubMed ID: 30256235
[TBL] [Abstract][Full Text] [Related]
22. Nuclear expression of β-catenin in endometrial hyperplasia as marker of premalignancy.
Travaglino A; Raffone A; Saccone G; Mascolo M; D'Alessandro P; Arduino B; Mollo A; Insabato L; Zullo F
APMIS; 2019 Nov; 127(11):699-709. PubMed ID: 31403731
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma.
Liu Y; Patel L; Mills GB; Lu KH; Sood AK; Ding L; Kucherlapati R; Mardis ER; Levine DA; Shmulevich I; Broaddus RR; Zhang W
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25214561
[TBL] [Abstract][Full Text] [Related]
24. Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma.
Cuevas D; Valls J; Gatius S; Roman-Canal B; Estaran E; Dorca E; Santacana M; Vaquero M; Eritja N; Velasco A; Matias-Guiu X
Virchows Arch; 2019 May; 474(5):585-598. PubMed ID: 30710169
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic Evaluation of CTNNB1 Mutations in High-Intermediate Risk Endometrial Endometrioid Carcinoma.
Haag JG; Wolsky RJ; Moroney MR; Sheren J; Sheeder J; Bitler BG; Corr BR
Int J Gynecol Pathol; 2023 Jan; 42(1):43-53. PubMed ID: 35283443
[TBL] [Abstract][Full Text] [Related]
26. Evidence for a Novel Endometrioid Carcinogenic Sequence in the Fallopian Tube With Unique Beta-Catenin Expression.
Brouwer J; Strickland KC; Ning G; Schmelkin CB; Kolin DL; Hecht J; Nucci MR; Mourits MJ; Xian W; Crum CP
Int J Gynecol Pathol; 2020 Mar; 39(2):163-169. PubMed ID: 31574529
[TBL] [Abstract][Full Text] [Related]
27. Diabetes mellitus and responsiveness of endometrial hyperplasia and early endometrial cancer to conservative treatment.
Raffone A; Travaglino A; Saccone G; Di Maio A; Mollo A; Mascolo M; De Rosa R; De Placido G; Insabato L; Zullo F
Gynecol Endocrinol; 2019 Nov; 35(11):932-937. PubMed ID: 31165649
[No Abstract] [Full Text] [Related]
28. β-catenin, Pax2, and Pten Panel Identifies Precancers Among Histologically Subdiagnostic Endometrial Lesions.
Aguilar M; Chen H; Sahoo SS; Zheng W; Grubman J; SoRelle JA; Lucas E; Castrillon DH
Am J Surg Pathol; 2023 May; 47(5):618-629. PubMed ID: 36939046
[TBL] [Abstract][Full Text] [Related]
29. Mismatch Repair Protein Expression in Endometrioid Intraepithelial Neoplasia/Atypical Hyperplasia: Should We Screen for Lynch Syndrome in Precancerous Lesions?
Lucas E; Chen H; Molberg K; Castrillon DH; Rivera Colon G; Li L; Hinson S; Thibodeaux J; Lea J; Miller DS; Zheng W
Int J Gynecol Pathol; 2019 Nov; 38(6):533-542. PubMed ID: 30383610
[TBL] [Abstract][Full Text] [Related]
30. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
[TBL] [Abstract][Full Text] [Related]
31. beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.
Moreno-Bueno G; Gamallo C; Pérez-Gallego L; de Mora JC; Suárez A; Palacios J
Diagn Mol Pathol; 2001 Jun; 10(2):116-22. PubMed ID: 11385321
[TBL] [Abstract][Full Text] [Related]
32. Endometrial Adenocarcinomas With No Specific Molecular Profile: Morphologic Features and Molecular Alterations of "Copy-number Low" Tumors.
Meljen VT; Mittenzwei R; Wong J; Puechl A; Whitaker R; Broadwater G; Hall AH; Bean SM; Bentley RC; Elvin JA; Berchuck A; Previs RA; Strickland KC
Int J Gynecol Pathol; 2021 Nov; 40(6):587-596. PubMed ID: 33720082
[TBL] [Abstract][Full Text] [Related]
33. PAX2 is regulated by estrogen/progesterone through promoter methylation in endometrioid adenocarcinoma and has an important role in carcinogenesis via the AKT/mTOR signaling pathway.
Chen H; Li L; Liu H; Qin P; Chen R; Liu S; Xiong H; Li Y; Yang Z; Xie M; Yang H; Jiang Q
J Pathol; 2024 Apr; 262(4):467-479. PubMed ID: 38185904
[TBL] [Abstract][Full Text] [Related]
34. Mesonephric-like adenocarcinoma of the ovary with squamoid morular metaplasia, aberrant β-catenin expression, and concurrent FGFR2 and CTNNB1 mutations: a case report.
Xu J; Park KJ; Rehrauer WM; Weisman PS
Virchows Arch; 2024 Jan; 484(1):147-150. PubMed ID: 36856760
[TBL] [Abstract][Full Text] [Related]
35. Nuclear β-catenin localization and mutation of the CTNNB1 gene: a context-dependent association.
Kim G; Kurnit KC; Djordjevic B; Singh C; Munsell MF; Wang WL; Lazar AJ; Zhang W; Broaddus R
Mod Pathol; 2018 Oct; 31(10):1553-1559. PubMed ID: 29795437
[TBL] [Abstract][Full Text] [Related]
36. Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations.
Jiang Y; Malouf GG; Zhang J; Zheng X; Chen Y; Thompson EJ; Weinstein JN; Yuan Y; Spano JP; Broaddus R; Tannir NM; Khayat D; Lu KH; Su X
Oncotarget; 2015 Nov; 6(37):39865-76. PubMed ID: 26431491
[TBL] [Abstract][Full Text] [Related]
37. PTEN mutations do not cause nuclear beta-catenin accumulation in endometrial carcinomas.
Wappenschmidt B; Wardelmann E; Gehrig A; Schöndorf T; Maass N; Bonatz G; Gassel AM; Pietsch T; Mallmann P; Weber BH; Schmutzler RK
Hum Pathol; 2004 Oct; 35(10):1260-5. PubMed ID: 15492994
[TBL] [Abstract][Full Text] [Related]
38. Frequent nuclear beta-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation.
Saegusa M; Okayasu I
J Pathol; 2001 May; 194(1):59-67. PubMed ID: 11329142
[TBL] [Abstract][Full Text] [Related]
39. Aberrant Cdx2 expression in endometrial lesions with squamous differentiation: important role of Cdx2 in squamous morula formation.
Wani Y; Notohara K; Saegusa M; Tsukayama C
Hum Pathol; 2008 Jul; 39(7):1072-9. PubMed ID: 18495206
[TBL] [Abstract][Full Text] [Related]
40. Use of clinicopathological factors to predict prognosis of fertility-sparing treatment for endometrial endometrioid carcinoma and atypical hyperplasia.
Zhang X; Zhao X; Wang C; Lu S; Wang Y; He Y; Wang J; Shen D
Oncol Lett; 2023 Feb; 25(2):52. PubMed ID: 36644134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]